Related Experiment Video

Updated: Jun 28, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biology

Jennifer A Marks1, Rohan Maniar2, Kavitha J Ramchandran3

  • 1Dana-Farber Cancer Institute, Boston, MA, USA. jennifer_marks@dfci.harvard.edu.

NPJ Precision Oncology
|June 26, 2026
PubMed

Insights

Thymic epithelial tumors (TETs) are rare cancers with unique immune traits and few treatments. This review explores molecular data and biomarkers to guide future precision-guided, combination therapies for better patient care.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Thymic epithelial tumors (TETs) are rare, diverse malignancies with complex immune interactions.
  • The association of TETs, particularly thymomas, with autoimmune diseases presents treatment challenges.
  • Limited prospective data and systemic treatment options exist for TETs.

Purpose of the Study:

  • To review molecular profiling and predictive biomarkers in TETs.
  • To explore novel therapeutic strategies for thymic epithelial tumors.
  • To identify priorities for future research, including trials, registries, and real-world data.

Main Methods:

  • Comprehensive literature review focusing on molecular profiling in TETs.
  • Analysis of existing data on predictive biomarkers for treatment response.
  • Examination of current and emerging systemic treatment modalities.

Main Results:

  • Molecular profiling reveals diverse genetic landscapes within TET subtypes.
  • Specific biomarkers show potential for predicting response to targeted therapies.
  • New treatment strategies are emerging, focusing on immune modulation and targeted agents.

Conclusions:

  • Precision-guided, combination-based treatments offer a promising future for TET management.
  • Enhanced access to expert, multidisciplinary care is crucial.
  • Global registries and real-world data are essential for advancing TET research and treatment.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...